Immunomodulation in autoimmune diseases.
Systemic autoimmune diseases are generally treated with immunosuppressive agents. In some instances immunomodulatory agents have shown promise in the treatment of certain types of autoimmune disorders. The in vitro and/or in vivo effects of some of these agents (glutaurine, ketoconazole, gutimine and its derivative) are demonstrated. Glutaurine exerts moderate immunostimulating activity, but fails to influence the clinical course of systemic lupus erythematosus. Although ketoconazole suppresses immune responses in vitro, it does not influence cellular reactivity of patients in vivo. The immunostimulatory activity of gutimine and its derivative (T 001) have been demonstrated in vitro, and need to be tested also in vivo.
Gergely
P
P
Second Department of Medicine, Semmelweis University, Budapest, Hungary.
Láng
I
I
Gonzalez-Cabello
R
R
Fehér
J
J
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D004341:Drug Evaluation; D005973:Glutamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006164:Guanylthiourea / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007654:Ketoconazole / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008214:Lymphocytes / Q000145:classification; D013654:Taurine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D005973:Glutamine; D013654:Taurine; C020903:glutaurine; D006164:Guanylthiourea; D007654:Ketoconazole